This assumption derives from the observation that NMO patients can be anti-AQP4 antibody positive for many years prior to the onset of the disease[9], and that peripherally administered pathogenic AQP4-specific antibodies do not spontaneously enter the CNS parenchyma of experimental animals[4,10]. Here, AQP4 is linked to neuromyelitis optica.